conference that will make the case for Cosentyx (secukinumab) in a highly competitive market. Cosentyx is a key drug for Novartis, as it is part of the company’s plan to replace lost sales from ...

Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy TA117 24 January 2007 24 January 2007 Methadone and buprenorphine ...

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders. According to GlobalData, Phase II drugs for Unspecified Dermatological ...

Objective To evaluate the effectiveness and safety of secukinumab in patients with a mucosal and articular Behçet’s phenotype resistant to conventional and biologic treatment. Methods A multicentre ...

A model showing how metallic bonds are formed - the first diagram shows the outer electrons in their atoms, and the second diagram shows that the electrons have become delocalised ...

Objectives To determine the relationship between synovial versus skin transcriptional/histological profiles in patients with active psoriatic arthritis (PsA) and ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Check out the nestjs-project-performance repository for examples using this alternative.